Document is current
Any future updates will be listed below
-
Authors
Pfaff, Elke
Schramm, Kathrin
Blattner-Johnson, Mirjam
Jones, Barbara C.
Stark, Sebastian
Balasubramanian, Gnana Prakash
Previti, Christopher
Autry, Robert J.
Fiesel, Petra
Sahm, Felix
Reuss, David
von Deimling, Andreas
van Tilburg, Cornelis M.
Pajtler, Kristian W.
Milde, Till
Dirksen, Uta
Kramm, Christof M.
von Bueren, André O.
Hutter, Caroline
de Wilde, Bram
Molenaar, Jan
Gerber, Nicolas U.
Lohi, Olli
Munthe-Kaas, Monica C.
Georgantzi, Kleopatra
Kazanowska, Bernarda
Zápotocký, Michal
Kattamis, Antonis
Filippidou, Maria
Fried, Iris
Pfister, Stefan M.
Witt, Olaf
Jones, David T. W.
-
Funding
Funding for this research was provided by:
Medical Faculty of Heidelberg University
Deutsches Krebsforschungszentrum (DKFZ)
- License Information
-
More Information
Article History
Received: 29 May 2025
Revised: 20 August 2025
Accepted: 27 September 2025
First Online: 11 October 2025
Declarations
:
: CvT: advisory boards for Alexion, Bayer, Novartis, and Roche, and travel support from Eli Lilly. All activities were outside the submitted work. AOvB: advisory and consulting roles for Alexion, Novartis. FS, AvD, SMP and DTWJ: founders and shareholders of Heidelberg Epignostix GmbH.
